Nebivololo Abc (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractile force. At the same time, it enhances nitric oxide release from the endothelium, causing blood vessels to relax. This dual action lowers systemic blood pressure and improves heart‑failure symptoms.

The exact dose of Nebivololo Abc is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any co‑existing health issues. Dosage adjustments are made during follow‑up visits to achieve optimal blood‑pressure control or heart‑failure management.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a β1‑selective blocker that also promotes nitric‑oxide‑mediated vasodilation, which can result in fewer metabolic side effects compared with non‑selective beta‑blockers. This unique profile may offer better tolerability for some patients, though therapeutic choice depends on individual clinical circumstances.

Nebivololo Abc should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Nebivololo Abc is taken orally, usually once daily, with or without food as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events, though uncommon, include severe bradycardia, atrioventricular block, bronchospasm in patients with reactive airway disease, and rare cases of liver injury or severe allergic reactions. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or signs of an allergic response.

Nebivololo Abc is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals with uncompensated heart failure. Clinicians should also exercise caution in patients with asthma, COPD, or significant hepatic impairment.